Systems Biology in Cancer Research and Drug DiscoveryAsfar S Azmi Springer Science & Business Media, 29.09.2012 - 423 Seiten Systems Biology in Cancer Research and Drug Discovery provides a unique collection of chapters, by world-class researchers, describing the use of integrated systems biology and network modeling in the cancer field where traditional tools have failed to deliver expected promise. This book touches four applications/aspects of systems biology (i) in understanding aberrant signaling in cancer (ii) in identifying biomarkers and prognostic markers especially focused on angiogenesis pathways (iii) in unwinding microRNAs complexity and (iv) in anticancer drug discovery and in clinical trial design. This book reviews the state-of-the-art knowledge and touches upon cutting edge newer and improved applications especially in the area of network modeling. It is aimed at an audience ranging from students, academics, basic researcher and clinicians in cancer research. This book is expected to benefit the field of translational cancer medicine by bridging the gap between basic researchers, computational biologists and clinicians who have one ultimate goal and that is to defeat cancer. |
Im Buch
Ergebnisse 1-5 von 71
... breast cancer cells: non-invasive MCF7 cells have much lower aerobic glucose consumption rates when compared to the highly invasive MDA-MB231 mammary cancer cell line (Schomack and Gilles 2003; Mazurek et al. 1997). The high rate of ...
... cancer initiation The glycolytic phenotype can be 'reversed' by appropriate manipulation of the microenvironment. In a previous study (D'Anselmi et al. 2011), we showed that breast cancer cells (MCF7 and MDA-MB231) growing in a ...
... cancer metabolic fingerprint. Mean Normalized Bending Energy values ... cancer cells exhibit high NBE values, whereas EMF treatment induces a dramatic two-fold ... breast cancer cells growing in different mechanical and structural ...
... breast cancer cells undergoing shape change, glycolytic fluxes were concomitantly reduced, with a parallel decrease in lactate, glutathione, and glutamine and other compounds. Namely for MDA-MB231 cell line, characterized by a truly ...
... breast cancer cells underwent a transition from a glycolytic towards an oxidative metabolic phenotype (modified from M. Bizzarri et al. (2010)) PC1 PC2 Factor Factor ppma Loadingb Metabolite c ppma Loadingb Metabolitec 3.23, 3.41, 3.71 ...
Inhalt
Systems Approaches to Understand Cancer Progression | 165 |
Systems and Network Biology in Decoding miRNA Complexity | 246 |
Network Modeling in Cancer Drug Discovery and Clinical Trials | 307 |
Erratum | 418 |
Index | 419 |